Gracell Biotechnologies (NASDAQ:GRCL) Downgraded by HC Wainwright to Neutral

HC Wainwright lowered shares of Gracell Biotechnologies (NASDAQ:GRCL – Free Report) from a buy rating to a neutral rating in a research note issued to investors on Tuesday, Marketbeat.com reports. HC Wainwright currently has $10.00 target price on the stock, down from their previous target price of $13.00. HC Wainwright also issued estimates for Gracell […]

Related Keywords

Stifel Nicolaus ,Schonfeld Strategic Advisors ,Tower Research Capital ,Citigroup ,Gracell Biotechnologies Inc ,Venture Partners Investment Advisor ,Cantor Fitzgerald ,Nasdaq ,Gracell Biotechnologies ,Free Report ,Gracell Biotechnologie ,Moderate Buy ,Get Free Report ,Bay Capital Management ,Capital Partners ,Strategic Advisors ,Research Capital ,Biotechnologies Inc ,Gracell Biotechnologies Daily ,Nasdaq Grcl ,Grcl ,Medical ,Downgrade ,Hc Wainwright ,